0001533615 false 0001533615 2022-05-11 2022-05-11 0001533615 us-gaap:CommonStockMember 2022-05-11 2022-05-11 0001533615 us-gaap:SeriesAPreferredStockMember 2022-05-11 2022-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 13, 2022 (May 11, 2022)

 

Global Medical REIT Inc.

(Exact name of registrant as specified in its charter)

 

Maryland 001-37815 46-4757266

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

2 Bethesda Metro Center, Suite 440

Bethesda, MD

20814

(Address of principal executive offices)

(Zip Code)

 

(202) 524-6851

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbols:   Name of each exchange on which registered:
Common Stock, par value $0.001 per share   GMRE   NYSE
Series A Preferred Stock, par value $0.001 per share   GMRE PrA   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the 2022 annual meeting of Global Medical REIT Inc. (the “Company”), the Company’s stockholders: (i) elected the eight nominated directors to the Company’s Board of Directors, each to serve until the Company’s 2023 annual meeting of stockholders and until her or his successor is duly elected and qualifies, (ii) approved, on an advisory basis, the compensation of the Company’s named executive officers, and (iii) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The full results of the matters voted on at the 2022 annual meeting of stockholders are set forth below:

 

Proposal 1 — Election of Directors:

 

Nominee for Director  For  Against  Abstain  Broker Non-Votes
Jeffrey M. Busch  42,941,919  2,277,422  150,259  10,577,481
Matthew Cypher  44,325,784  986,860  56,956  10,577,481
Ronald Marston  44,208,099  1,114,995  46,503  10,577,484
Roscoe Moore, Jr.  44,300,766  1,007,844  60,989  10,577,482
Henry E. Cole  44,918,473  402,754  48,374  10,577,480
Zhang Huiqi  45,081,576  236,932  51,091  10,577,482
Paula R. Crowley  45,101,550  213,263  54,787  10,577,481
Lori Wittman  44,333,467  982,056  54,077  10,577,481

 

 Proposal 2 — Advisory Vote on Named Executive Officer Compensation:

 

For  Against  Abstain  Broker Non-Votes
44,326,258  818,018  225,318  10,577,487

 

Proposal 3 — Ratification of Appointment of Independent Registered Public Accounting Firm:

 

For  Against  Abstain  Broker Non-Votes
55,785,212  84,797  77,072  0

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On May 13, 2022, the Company updated a presentation concerning the Company on its website, www.globalmedicalreit.com, on the “Investors” page. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein solely for purposes of this Item 7.01 disclosure. Such investor presentation shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 7.01, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)   Exhibits

 

Exhibit No.    Description
 99.1   Investor Presentation dated May 13, 2022.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Global Medical REIT Inc.
     
  By:  /s/ Jamie A. Barber
    Jamie A. Barber
    Secretary and General Counsel
     
Date:  May 13, 2022